Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Scholar Rock Holding (SRRK – Research Report). The associated price target was raised to $40.00. Andres Y. Maldonado ...

TD Cowen analyst Marc Frahm has maintained their bullish stance on SRRK stock, giving a Buy rating today. Marc Frahm has given his Buy rating due to a combination of factors including promising trial ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients Scholar Rock (SRRK), a Phase 3, clinical-stage ...

December S&P 500 E-Mini futures are down -0.20%, andDecember Nasdaq 100 E-Mini futures are down -0.21% this morning as investors assessed the potential policy impact of Donald Tru ...